Physician's Best Choice

DRUG2 trials

Sponsors

Angiochem Inc, J-Pharma Co., Ltd.

Conditions

Advanced Biliary Tract CancerBiliary Tract Cancer (BTC)Brain MetastasesHER2-negative Breast CancerLeptomeningeal CarcinomatosisLeptomeningeal Metastases

Phase 3

ANG1005 in Leptomeningeal Disease From Breast Cancer

Angiochem IncBrain Metastases, HER2-negative Breast Cancer, Leptomeningeal Carcinomatosis +1

Start: 2023-12-31End: 2024-12-31Target: 150Updated: 2023-04-24

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

RecruitingNCT07265674

J-Pharma Co., Ltd.Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)

Start: 2026-05-11End: 2027-10-01Target: 480Updated: 2026-07-01

Related Papers

Phase II trial of blood–brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma

Neuro-Oncology Advances2024-01-016 citations